Genetic determinants of HDL metabolism

Current Medicinal Chemistry

Volumn 21, Issue 25, 2014, Pages 2855-2863

  Ossoli, A ^a   Gomaraschi, M ^a   Franceschini, G ^a   Calabresi, L ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

ABC transporters; Cholesteryl ester transfer protein; High density lipoproteins; Lecithin: cholesterol acyltransferase

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; SCAVENGER RECEPTOR BI; TRIACYLGLYCEROL LIPASE; APOLIPOPROTEIN; MEMBRANE PROTEIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEREDITY; HIGH DENSITY LIPOPROTEIN METABOLISM; HUMAN; LIPID COMPOSITION; LIPOGENESIS; LIPOLYSIS; LIPOPROTEIN METABOLISM; METABOLIC REGULATION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; GENETICS; METABOLISM; PROTEIN TRANSPORT;

APOLIPOPROTEINS; GENETIC VARIATION; HUMANS; LIPOPROTEINS, HDL; MEMBRANE PROTEINS; PROTEIN TRANSPORT;

EID: 84906086701     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140303154452     Document Type: Article

References (109)

1. Ikewaki, K.; Rader, D.J.; Schaefer, J.R.; Fairwell, T.; Zech, L.A.; Brewer, H.B.Jr. Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. J. Lipid Res., 1993, 34, 2207-2215.
2. Eisenberg, S. High density lipoprotein metabolism. J. Lipid Res., 1984, 25, 1017-1059.
3. Chisholm, J.W.; Burleson, E.R.; Shelness, G.S.; Parks, J.S. ApoA-I secretion from HepG2 cells. Evidence for the secretion of both lipid-poor apoA-I and intracellularly assembled nascent HDL. J. Lipid Res., 2002, 43(1), 36-44.
4. Kiss, R.S.; McManus, D.C.; Franklin, V.; Tan, W.L.; McKenzie, A.; Chimini, G.; Marcel, Y.L. The lipidation by hepatocytes of human apolipoprotein A-I occurs by both ABCA1-dependent and -independent pathways. J. Biol. Chem., 2003, 278(12), 10119-10127.
5. Tsujita, M.; Wu, C.A.; be-Dohmae, S.; Usui, S.; Okazaki, M.; Yokoyama, S. On the hepatic mechanism of HDL assembly by the ABCA1/apoA-I pathway. J. Lipid Res., 2005, 46(1), 154-162.
6. Jonas, A. Lecithin cholesterol acyltransferase. Biochim. Biophys. Acta, 2000, 1529, 245-256.
7. Zechner, R.; Dieplinger, H.; Steyer, H.; Groener, J.E.; Calvert, G.D.; Kostner, G.M. In vitro formation of HDL-2 from HDL-3 and triacylglycerol-rich lipoproteins by the action of lecithin: cholesterol acyltransferase and cholesterol ester transfer lipoprotein. Biochim. Biophys. Acta, 1987, 918, 27-36.
8. Clay, M.A.; Newnham, H.H.; Forte, T.M.; Barter, P.J. Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apo A-I from HDL and subsequent formation of discoidal HDL. Biochim. Biophys. Acta, 1992, 1124, 52-58.
9. Jahangiri, A.; Rader, D.J.; Marchadier, D.; Curtiss, L.K.; Bonnet, D.J.; Rye, K.A. Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I. J. Lipid Res., 2005, 46(5), 896-903.
10. Jauhiainen, M.; Metso, J.; Pahlman, R.; Blomqvist, S.; van Tol, A.; Ehnholm, C. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J. Biol. Chem., 1993, 268, 4032-4036.
11. Rye, K.A.; Barter, P.J. Formation and metabolism of prebetamigrating, lipid-poor apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol., 2004, 24(3), 421-428.
12. Rigotti, A.; Trigatti, B.; Babitt, J.; Penman, M.; Xu, S.; Krieger, M. Scavenger receptor BI-a cell surface receptor for high density lipoprotein. Curr. Opin. Lipidol., 1997, 8, 181-188.
13. Wang, N.; Arai, T.; Ji, Y.; Rinninger, F.; Tall, A.R. Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice. J. Biol. Chem., 1998, 273(49), 32920-32926.
14. Webb, N.R.; De Beer, M.C.; Asztalos, B.F.; Whitaker, N.; Van der Westhuyzen, D.R.; De Beer, F.C. Remodeling of HDL remnants generated by scavenger receptor class B type I. J. Lipid Res., 2004, 45(9), 1666-1673.
15. Segrest, J.P.; Jones, M.K.; De Loof, H.; Brouillette, C.G.; Venkatachalapathi, Y.V.; Anantharamaiah, G.M. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J. Lipid Res., 1992, 33, 141-166.
16. Tanaka, M.; Dhanasekaran, P.; Nguyen, D.; Ohta, S.; Lund-Katz, S.; Phillips, M.C.; Saito, H. Contributions of the N-and C-terminal helical segments to the lipid-free structure and lipid interaction of apolipoprotein a-I. Biochemistry, 2006, 45(34), 10351-10358.
17. Chroni, A.; Koukos, G.; Duka, A.; Zannis, V.I. The carboxyterminal region of apoA-I Is required for the ABCA1-dependent formation of alpha-HDL but not prebeta-HDL particles in vivo. Biochemistry, 2007, 46(19), 5697-5708.
18. Sorci-Thomas, M.G.; Thomas, M.J. The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc. Med., 2002, 12(3), 121-128.
19. Oldoni, F.; Sinke, R.J.; Kuivenhoven, J.A. Mendelian disorders of high-density lipoprotein metabolism. Circ. Res., 2014, 114(1), 124-142.
20. Franceschini, G. Apolipoprotein function in health and disease: insights from natural mutations. Eur. J. Clin. Invest., 1996, 26, 733-746.
21. Franceschini, G.; Sirtori, C.R.; Capurso, A.; Weisgraber, K.H.; Mahley, R.W. A-IMilanoapoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an italian family. J. Clin. Invest., 1980, 66, 892-900.
22. Weisgraber, K.H.; Rall, S.C., Jr.; Bersot, T.P.; Mahley, R.W.; Franceschini, G.; Sirtori, C.R. Apolipoprotein A-IMilano. Detection of normal AI in affected subjects and evidence for a cysteine for arginine substitution in the variant AI. J. Biol. Chem., 1983, 258, 2508-2513.
23. Franceschini, G.; Calabresi, L.; Tosi, C.; Sirtori, C.R.; Fragiacomo, G.C.; Noseda, G.; Gong, E.L.; Blanche, P.J.; Nichols, A.V. Apolipoprotein A-IMilano. Correlation between lipoproteinsubclass distribution and triglyceridemia. Arteriosclerosis, 1987, 7, 426-435.
24. Franceschini, G.; Baio, M.; Calabresi, L.; Sirtori, C.R.; Cheung, M.C. Apolipoprotein A-IMilano. Partial lecithin:cholesterol acyltransferase deficiency due to low levels of a functional enzyme. Biochim. Biophys. Acta, 1990, 1043, 1-6.
25. Gualandri, V.; Franceschini, G.; Sirtori, C.R.; Gianfranceschi, G.; Orsini, G.B.; Cerrone, A.; Menotti, A. A-IMilanoapoprotein. Identification of the complete kindred and evidence of a dominant genetic transmission. Am. J. Hum. Genet., 1985, 37, 1083-1097.
26. Favari, E.; Gomaraschi, M.; Zanotti, I.; Bernini, F.; Lee-Rueckert, M.; Kovanen, P.T.; Sirtori, C.R.; Franceschini, G.; Calabresi, L. A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-IMilano dimer effectively promotes ATPbinding cassette A1-mediated cell cholesterol efflux. J. Biol. Chem., 2007, 282(8), 5125-5132.
27. Rall, S.C., Jr.; Weisgraber, K.H.; Mahley, R.W.; Ogawa, Y.; Fielding, C.J.; Utermann, G.; Haas, J.; Steinmetz, A.; Menzel, H.J.; Assmann, G. Abnormal lecithin:cholesterol acyltransferase activation by a human apolipoprotein A-I variant in which a single lysine residue is deleted. J. Biol. Chem., 1984, 259, 10063-10070.
28. Utermann, G.; Haas, J.; Steinmetz, A.; Paetzold, R.; Rall, S.C., Jr.; Weisgraber, K.H.; Mahley, R.W. Apolipoprotein A-IGiessen(Pro143->Arg). A mutant that is defective in activating lecithin:cholesterol acyltransferase. Eur. J. Biochem., 1984, 144, 325-331.
29. Takada, Y.; Sasaki, J.; Ogata, S.; Nakanishi, T.; Ikenara, Y.; Arakawa, K. Isolation and characterizarion of human apolipoprotein AI Fukuoka (110Glu ->Lys). A novel apolipoprotein variant. Biochim. Biophys. Acta, 1990, 1043, 169-176.
30. Huang, W.; Sasaki, J.; Matsunaga, A.; Nanimatsu, H.; Moriyama, K.; Han, H.; Kugi, M.; Koga, T.; Yamaguchi, K.; Arakawa, K. A novel homozygous missense mutation in the apo A-I gene with apo A-I deficiency. Arterioscler. Thromb. Vasc. Biol., 1998, 18, 389-396.
31. Moriyama, K.; Sasaki, J.; Matsunaga, A.; Takada, Y.; Kagimoto, M.; Arakawa, K. Identification of two apolipoprotein variants, A-I Karatsu (Tyr 100->His) and A-I Kurume (His 162->Gln). Clin. Genet., 1996, 49, 79-84.
32. Calabresi, L.; Vecchio, G.; Frigerio, F.; Vavassori, L.; Sirtori, C.R.; Franceschini, G. Reconstituted high-density lipoproteins with a disulfide-linked apolipoprotein A-I dimer: evidence for restricted particle size heterogeneity. Biochemistry, 1997, 36, 12428-12433.
33. Daum, U.; Langer, C.; Duverger, N.; Emmanuel, F.; Benoit, P.; Denefle, P.; Chirazi, A.; Cullen, P.; Pritchard, P.H.; Bruckert, E.; Assmann, G.; von Eckardstein, A. Apolipoprotein A-I (R151C)Paris is defective in activation of lecithin: cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol efflux. J. Mol. Med., 1999, 77, 614-622.
34. Ponsin, G.; Gotto, A.M., Jr.; Utermann, G.; Pownall, H.J. Abnormal interaction of the human apolipoprotein A-I variant [Lys107->0] with high density lipoproteins. Biochem. Biophys. Res. Commun., 1985, 133, 856-862.
35. Jonas, A.; von Eckardstein, A.; Kezdy, K.E.; Steinmetz, A.; Assmann, G. Structural and functional properties of reconstitued high density lipoprotein discs prepared with six apolipoprotein A-I variants. J. Lipid Res., 1991, 32, 97-106.
36. Tilly-Kiesi, M.; Zhang, Q.; Ehnholm, S.; Kahri, J.; Lahdenpera, S.; Ehnholm, C.; Taskinen, M.R. ApoA-IHelsinki (Lys107->0) associated with reduced HDL cholesterol and LpA-I:A-II deficiency. Arterioscler. Thromb. Vasc. Biol., 1995, 15, 1294-1306.
37. Obici, L.; Franceschini, G.; Calabresi, L.; Giorgetti, S.; Stoppini, M.; Merlini, G.; Bellotti, V. Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid., 2006, 13(4), 191-205.
38. Gomaraschi, M.; Obici, L.; Simonelli, S.; Gregorini, G.; negrinelli, A.; Merlini, G.; Franceschini, G.; Calabresi, L. Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations. Clin. Chim. Acta, 2011, 412(13-14), 1262-1265.
39. Marchesi, M.; Parolini, C.; Valetti, C.; Mangione, P.; Obici, L.; Giorgetti, S.; Raimondi, S.; Donadei, S.; Gregorini, G.; Merlini, G.; Stoppini, M.; Chiesa, G.; Bellotti, V. The intracellularquality control system down-regulates the secretion of amyloidogenicapolipoprotein A-I variants: A possible impact on the naturalhistory of the disease. Biochim. Biophys. Acta, 2011, 1812(1), 87-93.
40. Rader, D.J.; Gregg, R.E.; Meng, M.S.; Schaefer, J.R.; Zech, L.A.; Benson, M.D.; Brewer, H.B. Jr. In vivo metabolism of a mutant apolipoprotein, apoA-IIowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. J. Lipid Res., 1992, 33, 755-763.
41. Lux, S.E.; John, K.M.; Breslow, J.L. Isolation and characterization of the tryptic and cyanogen bromide peptides of apoLp-Gln-II (apoA-II), a plasma high density apolipoprotein. J. Biol. Chem., 1972, 247, 7519-7527.
42. Deeb, S.S.; Takata, K.; Peng, R.; Kajiyama, G.; Albers, J.J. A splice-junction mutation responsible for familial apolipoprotein AII gene deficiency. Am. J. Hum. Genet., 1990, 46, 822-827.
43. Oram, J.F.; Heinecke, J.W. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol. Rev., 2005, 85(4), 1343-1372.
44. Rust, S.; Rosier, M.; Funke, H.; Real, J.; Amoura, Z.; Piette, J.C.; Deleuze, J.F.; Brewer, H.B.; Duverger, N.; Denefle, P.; Assmann, G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet., 1999, 22, 352-355.
45. Bodzioch, M.; Orso, E.; Klucken, J.; Langmann, T.; Bottcher, A.; Diederich, W.; Drobnik, W.; Barlage, S.; Buchler, C.; Porsch-Ozcurumez, M.; Kaminski, W.E.; Hahmann, H.W.; Oette, K.; Rothe, G.; Aslanidis, C.; Lackner, K.J.; Schmitz, G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet., 1999, 22, 347-351.
46. Brooks-Wilson, A.; Marcil, M.; Clee, S.M.; Zhang, L.H.; Roomp, K.; van Dam, M.; Yu, L.; Brewer, C.; Collins, J.A.; Molhuizen, H.O.; Loubser, O.; Ouelette, B.F.; Fichter, K.; Ashbourne-Excoffon, K.J.; Sensen, C.W.; Scherer, S.; Mott, S.; Denis, M.; Martindale, D.; Frohlich, J.; Morgan, K.; Koop, B.; Pimstone, S.; Kastelein, J.J.; Hayden, M.R. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet., 1999, 22, 336-345.
47. Francis, G.A.; Knopp, R.H.; Oram, J.F. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier Disease. J. Clin. Invest., 1995, 96, 78-87.
48. Cohen, J.C.; Kiss, R.S.; Pertsemlidis, A.; Marcel, Y.L.; McPherson, R.; Hobbs, H.H. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science, 2004, 305(5685), 869-872.
49. Frikke-Schmidt, R.; Nordestgaard, B.G.; Stene, M.C.; Sethi, A.A.; Remaley, A.T.; Schnohr, P.; Grande, P.; Tybjaerg-Hansen, A. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA, 2008, 299(21), 2524-2532.
50. Singaraja, R.R.; Visscher, H.; James, E.R.; Chroni, A.; Coutinho, J.M.; Brunham, L.R.; Kang, M.H.; Zannis, V.I.; Chimini, G.; Hayden, M.R. Specific mutations in ABCA1 have discrete effects on ABCA1 function and lipid phenotypes both in vivo and in vitro. Circ. Res., 2006, 99(4), 389-397.
51. Kathiresan, S.; Willer, C.J.; Peloso, G.M.; Demissie, S.; Musunuru, K.; Schadt, E.E.; Kaplan, L.; Bennett, D.; Li, Y.; Tanaka, T.; Voight, B.F.; Bonnycastle, L.L.; Jackson, A.U.; Crawford, G.; Surti, A.; Guiducci, C.; Burtt, N.P.; Parish, S.; Clarke, R.; Zelenika, D.; Kubalanza, K.A.; Morken, M.A.; Scott, L.J.; Stringham, H.M.; Galan, P.; Swift, A.J.; Kuusisto, J.; Bergman, R.N.; Sundvall, J.; Laakso, M.; Ferrucci, L.; Scheet, P.; Sanna, S.; Uda, M.; Yang, Q.; Lunetta, K.L.; Dupuis, J.; de Bakker, P.I.; O'Donnell, C.J.; Chambers, J.C.; Kooner, J.S.; Hercberg, S.; Meneton, P.; Lakatta, E.G.; Scuteri, A.; Schlessinger, D.; Tuomilehto, J.; Collins, F.S.; Groop, L.; Altshuler, D.; Collins, R.; Lathrop, G.M.; Melander, O.; Salomaa, V.; Peltonen, L.; Orho-Melander, M.; Ordovas, J.M.; Boehnke, M.; Abecasis, G.R.; Mohlke, K.L.; Cupples, L.A. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat. Genet., 2009, 41(1), 56-65.
52. Frikke-Schmidt, R.; Nordestgaard, B.G.; Jensen, G.B.; Tybjaerg-Hansen, A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J. Clin. Invest., 2004, 114(9), 1343-1353.
53. Schaefer, E.J.; Blum, C.B.; Levy, R.I.; Jenkins, L.L.; Alaupovic, P.; Foster, D.M.; Brewer, H.B., Jr. Metabolism of high-density lipoprotein apolipoproteins in Tangier disease. N. Engl. J. Med., 1978, 905-910.
54. Huang, Y.; von Eckardstein, A.; Wu, S.; Langer, C.; Assmann, G. Generation of pre-beta 1-HDL and conversion into alpha-HDL. Evidence for disturbed HDL conversion in Tangier disease. Arterioscler. Thromb. Vasc. Biol., 1995, 15, 1746-1754.
55. Brousseau, M.E.; Eberhart, G.P.; Dupuis, J.; Asztalos, B.F.; Goldkamp, A.L.; Schaefer, E.J.; Freeman, M.W. Cellular cholesterol efflux in heterozygotes for tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size. J. Lipid Res., 2000, 41, 1125-1135.
56. Jessup, W.; Gelissen, I.C.; Gaus, K.; Kritharides, L. Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr. Opin. Lipidol., 2006, 17(3), 247-257.
57. Favari, E.; Calabresi, L.; Adorni, M.P.; Jessup, W.; Simonelli, S.; Franceschini, G.; Bernini, F. Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry, 2009, 48(46), 11067-11074.
58. Klucken, J.; Buchler, C.; Orso, E.; Kaminski, W.E.; Porsch-Ozcurumez, M.; Liebisch, G.; Kapinsky, M.; Diederich, W.; Drobnik, W.; Dean, M.; Allikmets, R.; Schmitz, G. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc. Natl. Acad. Sci. USA, 2000, 97, 817-822.
59. Abellan, R.; Mansego, M.L.; Martinez-Hervas, S.; Martin-Escudero, J.C.; Carmena, R.; Real, J.T.; Redon, J.; Castrodeza-Sanz, J.J.; Chaves, F.J. Association of selected ABC gene family single nucleotide polymorphisms with postprandial lipoproteins: results from the population-based Hortega study. Atherosclerosis, 2010, 211(1), 203-209.
60. Norum, K. R.; Gjone, E. Familial serum-cholesterol esterification failure. A new inborn error of metabolism. Biochim. Biophys. Acta, 1967, 144(3), 698-700.
61. Available from: http://www.lcat.it/database.html. Interrogated January 20. 2014.
62. Calabresi, L.; Moleri, E.; Franceschini, G. LCAT deficiency: molecular genetics, lipid/lipoprotein phenotype and atherosclerosis. Future Lipidol., 2006, 1, 241-245.
63. Asztalos, B.F.; Schaefer, E.J.; Horvath, K.V.; Yamashita, S.; Miller, M.; Franceschini, G.; Calabresi, L. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J. Lipid Res., 2007, 48(3), 592-599.
64. Rader, D.J.; Ikewaki, K.; Duverger, N.; Schmidt, H.; Pritchard, H.; Frohlich, J.J.; Clerc, M.; Dumon, M.F.; Fairwell, T.; Zech, L.; Santamarina-Fojo, S.; Brewer, H.B. Jr. Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin:cholesterol acyltransferase deficiency and fish-eye disease. J. Clin. Invest., 1994, 93(1), 321-330.
65. Calabresi, L.; Favari, E.; Moleri, E.; Adorni, M.P.; Pedrelli, M.; Costa, S.; Jessup, W.; Gelissen, I.C.; Kovanen, P.T.; Bernini, F.; Franceschini, G. Functional LCAT is not required for macrophage cholesterol efflux to human serum. Atherosclerosis, 2009, 204(1), 141-146.
66. Calabresi, L.; Pisciotta, L.; Costantin, A.; Frigerio, I.; Eberini, I.; Alessandrini, P.; Arca, M.; Bon, G.B.; Boscutti, G.; Busnach, G.; Frasca, G.; Gesualdo, L.; Gigante, M.; Lupattelli, G.; Montali, A.; Pizzolitto, S.; Rabbone, I.; Rolleri, M.; Ruotolo, G.; Sampietro, T.; Sessa, A.; Vaudo, G.; Cantafora, A.; Veglia, F.; Calandra, S.; Bertolini, S.; Franceschini, G. The molecularbasis of lecithin: cholesterolacyltransferasedeficiencysyndromes: a comprehensivestudy of molecular and biochemicalfindings in 13 unrelatedItalian families. Arterioscler. Thromb. Vasc. Biol., 2005, 25(9), 1972-1978.
67. Brunzell, J.D.; Deeb, S.S. Familial lipoprotein lipase deficiency, apoC-II deficiency, and hepatic lipase deficiency. In The Metabolic and Molecular Bases of Inherited Diseases, Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., Eds.; McGraw-Hill: New York, 2001; pp 2789-2815.
68. Barrans, A.; Collet, X.; Barbaras, R.; Jaspard, B.; Manent, J.; Vieu, C.; Chap, H.; Perret, B. Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases. J. Biol. Chem., 1994, 269, 11572-11577.
69. Clay, M.A.; Newnham, H.H.; Barter, P.J. Hepatic lipase promotes a loss of apolipoprotein A-I from triglyceride-enriched human high density lipoproteins during incubation in vitro. Arterioscler. Thromb., 1991, 11, 415-422.
70. Hime, N.J.; Drew, K.J.; Hahn, C.; Barter, P.J.; Rye, K.A. Apolipoprotein E enhances hepatic lipase-mediated hydrolysis of reconstituted high-density lipoprotein phospholipid and triacylglycerol in an isoform-dependent manner. Biochemistry, 2004, 43(38), 12306-12314.
71. Hime, N.J.; Barter, P.J.; Rye, K.A. Evidence that apolipoprotein AI facilitates hepatic lipase-mediated phospholipid hydrolysis in reconstituted hdl containing apolipoprotein A-II. Biochemistry, 2001, 40, 5496-5505.
72. Hime, N.J.; Barter, P.J.; Rye, K.A. The influence of apolipoproteins on the hepatic lipase-mediated hydrolysis of high density lipoprotein phospholipid and triacylglycerol. J. Biol. Chem., 1998, 273, 27191-27198.
73. Santamarina-Fojo, S.; Gonzalez-Navarro, H.; Freeman, L.; Wagner, E.; Nong, Z. Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler. Thromb. Vasc. Biol., 2004, 24(10), 1750-1754.
74. Ruel, I.L.; Couture, P.; Cohn, J.S.; Bensadoun, A.; Marcil, M.; Lamarche, B. Evidence that hepatic lipase deficiency in humans is not associated with proatherogenic changes in HDL composition and metabolism. J. Lipid Res., 2004, 45(8), 1528-1537.
75. Tilly-Kiesi, M.; Schaefer, E.J.; Knudsen, P.; Welty, F.K.; Dolnikowski, G.G.; Taskinen, M. R.; Lichtenstein, A. H. Lipoprotein metabolism in subjects with hepatic lipase deficiency. Metabolism, 2004, 53(4), 520-525.
76. Guerra, R.; Wang, J.; Grundy, S.M.; Cohen, J.C. A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc. Natl. Acad. Sci. USA, 1997, 94, 4532-4537.
77. Jaye, M.; Lynch, K.J.; Krawiec, J.; Marchadier, D.; Maugeais, C.; Doan, K.; South, V.; Amin, D.; Perrone, M.; Rader, D.J. A novel endothelial-derived lipase that modulates HDL metabolism. Nat. Genet., 1999, 21, 424-428.
78. Edmondson, A.C.; Brown, R.J.; Kathiresan, S.; Cupples, L.A.; Demissie, S.; Manning, A.K.; Jensen, M.K.; Rimm, E.B.; Wang, J.; Rodrigues, A.; Bamba, V.; Khetarpal, S.A.; Wolfe, M.L.; Derohannessian, S.; Li, M.; Reilly, M.P.; Aberle, J.; Evans, D.; Hegele, R.A.; Rader, D.J. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J. Clin. Invest., 2009, 119(4), 1042-1050.
79. Brown, R.J.; Edmondson, A.C.; Griffon, N.; Hill, T.B.; Fuki, I.V.; Badellino, K.O.; Li, M.; Wolfe, M.L.; Reilly, M.P.; Rader, D.J. A naturally occurring variant of endothelial lipase associated with elevated HDL exhibits impaired synthesis. J. Lipid Res., 2009, 50, 1910-1916.
80. Singaraja, R.R.; Sivapalaratnam, S.; Hovingh, K.; Dube, M.P.; Castro-Perez, J.; Collins, H.L.; Adelman, S.J.; Riwanto, M.; Manz, J.; Hubbard, B.; Tietjen, I.; Wong, K.; Mitnaul, L. J.; van, H.M.; Lin, L.; Roddy, T.A.; McEwen, J.; linge-Thie, G.; van Vark-van der Zee; Verwoert, G.; Winther, M.; van, D.C.; Hofman, A.; Trip, M.D.; Marais, A.D.; Asztalos, B.; Landmesser, U.; Sijbrands, E.; Kastelein, J.J.; Hayden, M.R. The Impact of Partial and Complete Loss-of-Function Mutations in Endothelial Lipase on High-Density Lipoprotein Levels and Functionality in Humans. Circ. Cardiovasc. Genet., 2013, 6(1), 54-62.
81. deLemos, A.S.; Wolfe, M.L.; Long, C.J.; Sivapackianathan, R.; Rader, D.J. Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation, 2002, 106(11), 1321-1326.
82. Drayna, D.; Jarnagin, J.; McLean, J.W.; Henzel, W.; Kohr, W.; Fielding, C.J.; Lawn, R.M. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature, 1987, 327, 632-634.
83. Bruce, C.; Tall, A.R. Cholesteryl ester transfer proteins, reverse cholesterol transport, and atherosclerosis. Curr. Opin. Lipidol., 1995, 6, 306-311.
84. Rye, K.A.; Hime, N.J.; Barter, P.J. The influence of cholesteryl ester transfer protein on the composition, size, and structure of spherical, reconstituted high density lipoproteins. J. Biol. Chem., 1995, 270, 189-196.
85. van der Steeg, W.A.; Hovingh, G.K.; Klerkx, A.H.; Hutten, B.A.; Nootenboom, I.C.; Levels, J.H.; Van, T.A.; linga-Thie, G.M.; Zwinderman, A.H.; Kastelein, J.J.; Kuivenhoven, J.A. Cholesteryl ester transfer protein and hyperalphalipoproteinemia in Caucasians. J. Lipid Res., 2007, 48(3), 674-682.
86. Cefalu, A.B.; Noto, D.; Magnolo, L.; Pinotti, E.; Gomaraschi, M.; Martini, S.; Vigna, G.B.; Calabresi, L.; Tarugi, P.; Averna, M.R. Novelmutations of CETP gene in Italiansubjects with hyeralphalipoproteinemia. Atherosclerosis, 2009, 204(1), 202-207.
87. Calabresi, L.; Nilsson, P.; Pinotti, E.; Gomaraschi, M.; Favari, E.; Adorni, M.P.; Bernini, F.; Sirtori, C.R.; Calandra, S.; Franceschini, G.; Tarugi, P. A novelhomozygousmutation in CETP gene as a cause of CETP deficiency in a caucasiankindred. Atherosclerosis, 2009, 205(2), 506-511.
88. Johannsen, T.H.; Frikke-Schmidt, R.; Schou, J.; Nordestgaard, B.G.; Tybjærg-Hansen, A. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J. Am. Coll. Cardiol., 2012, 60(20), 2041-2048.
89. Asztalos, B.F.; Horvath, K.V.; Kajinami, K.; Nartsupha, C.; Cox, C.E.; Batista, M.; Schaefer, E.J.; Inazu, A.; Mabuchi, H. Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J. Lipid Res., 2004, 45(3), 448-455.
90. Ikewaki, K.; Rader, D.J.; Sakamoto, T.; Nishiwaki, M.; Wakimoto, N.; Schaefer, J.R.; Ishikawa, T.; Fairwell, T.; Zech, L.A.; Nakamura, H.; Nagano, M.; Brewer, H.B. Jr. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J. Clin. Invest., 1993, 92, 1650-1658.
91. Mulya, A.; Lee, J.Y.; Gebre, A.K.; Thomas, M.J.; Colvin, P.L.; Parks, J.S. Minimal lipidation of pre-beta HDL by ABCA1 results in reduced ability to interact with ABCA1. Arterioscler. Thromb. Vasc. Biol., 2007, 27(8), 1828-1836.
92. Thompson, A.; Di, A.E.; Sarwar, N.; Erqou, S.; Saleheen, D.; Dullaart, R.P.; Keavney, B.; Ye, Z.; Danesh, J. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA, 2008, 299(23), 2777-2788.
93. Tu, A.Y.; Nishida, H.I.; Nishida, T. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J. Biol. Chem., 1993, 268, 23098-23105.
94. Engler, M.B.; Pullinger, C.R.; Malloy, M.J.; Natanzon, Y.; Kulkarni, M.V.; Song, J.; Eng, C.; Huuskonen, J.; Rivera, C.; Poon, A.; Bensley, M.; Sehnert, A.; Zellner, C.; Kane, J.; Aouizerat, B.E. Genetic variation in phospholipid transfer protein modulates lipoprotein profiles in hyperalphalipoproteinemia. Metabolism, 2008, 57(12), 1719-1724.
95. Vergeer, M.; Boekholdt, S.M.; Sandhu, M.S.; Ricketts, S.L.; Wareham, N.J.; Brown, M.J.; de, F.U.; Leander, K.; Gigante, B.; Kavousi, M.; Hofman, A.; Uitterlinden, A.G.; van Duijn, C.M.; Witteman, J.C.; Jukema, J.W.; Schadt, E.E.; van der, S.E.; Kastelein, J.J.; Khaw, K.T.; Dullaart, R.P.; Van, T.A.; Trip, M.D.; linga-Thie, G.M. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation, 2010, 122(5), 470-477.
96. Acton, S.; Rigotti, A.; Landschulz, K.T.; Xu, S.; Hobbs, H.H.; Krieger, M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science, 1996, 271, 518-520.
97. Brundert, M.; Heeren, J.; Bahar-Bayansar, M.; Ewert, A.; Moore, K.J.; Rinninger, F. Selective uptake of HDL cholesteryl esters and cholesterol efflux from mouse peritoneal macrophages independent of SR-BI. J. Lipid Res., 2006, 47(11), 2408-2421.
98. Ji, Y.; Jian, B.; Wang, N.; Sun, Y.; Moya, M.L.; Phillips, M.C.; Rothblat, G.H.; Swaney, J.B.; Tall, A.R. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J. Biol. Chem., 1997, 272, 20982-20985.
99. Vergeer, M.; Korporaal, S.J.; Franssen, R.; Meurs, I.; Out, R.; Hovingh, G.K.; Hoekstra, M.; Sierts, J.A.; linga-Thie, G.M.; Motazacker, M.M.; Holleboom, A.G.; van Berkel, T.J.; Kastelein, J.J.; Van, E.M.; Kuivenhoven, J.A. Genetic variant of the scavenger receptor BI in humans. N. Engl. J. Med., 2011, 364(2), 136-145.
100. Brunham, L.; Tietjen, I.; Bochem, A.; Singaraja, R.; Franchini, P.; Radomski, C.; Mattice, M.; Legendre, A.; Hovingh, G.; Kastelein, J.; Hayden, M. Novel mutations in scavenger receptor BI associated with high HDL cholesterol in humans. Clin. Genet., 2011, 79(6), 575-581.
101. Chadwick, A.C.; Sahoo, D. Functional Characterization of Newly-Discovered Mutations in Human SR-BI. PLoS One, 2012, 7(9), e45660.
102. Voight, B.F.; Peloso, G.M.; Orho-Melander, M.; Frikke-Schmidt, R.; Barbalic, M.; Jensen, M.K.; Hindy, G.; Holm, H.; Ding, E.L.; Johnson, T.; Schunkert, H.; Samani, N.J.; Clarke, R.; Hopewell, J.C.; Thompson, J.F.; Li, M.; Thorleifsson, G.; Newton-Cheh, C.; Musunuru, K.; Pirruccello, J.P.; Saleheen, D.; Chen, L.; Stewart, A.; Schillert, A.; Thorsteinsdottir, U.; Thorgeirsson, G.; Anand, S.; Engert, J.C.; Morgan, T.; Spertus, J.; Stoll, M.; Berger, K.; Martinelli, N.; Girelli, D.; McKeown, P.P.; Patterson, C.C.; Epstein, S.E.; Devaney, J.; Burnett, M.S.; Mooser, V.; Ripatti, S.; Surakka, I.; Nieminen, M.S.; Sinisalo, J.; Lokki, M.L.; Perola, M.; Havulinna, A.; de, F.U.; Gigante, B.; Ingelsson, E.; Zeller, T.; Wild, P.; de Bakker, P.I.; Klungel, O.H.; Maitland-van der Zee, A.H.; Peters, B.J.; de, B.A.; Grobbee, D.E.; Kamphuisen, P.W.; Deneer, V.H.; Elbers, C.C.; Onland-Moret, N.C.; Hofker, M.H.; Wijmenga, C.; Verschuren, W.M.; Boer, J.M.; van der Schouw, Y.T.; Rasheed, A.; Frossard, P.; Demissie, S.; Willer, C.; Do, R.; Ordovas, J.M.; Abecasis, G.R.; Boehnke, M.; Mohlke, K.L.; Daly, M.J.; Guiducci, C.; Burtt, N.P.; Surti, A.; Gonzalez, E.; Purcell, S.; Gabriel, S.; Marrugat, J.; Peden, J.; Erdmann, J.; Diemert, P.; Willenborg, C.; Konig, I.R.; Fischer, M.; Hengstenberg, C.; Ziegler, A.; Buysschaert, I.; Lambrechts, D.; Van de, W.F.; Fox, K.A.; El Mokhtari, N.E.; Rubin, D.; Schrezenmeir, J.; Schreiber, S.; Schafer, A.; Danesh, J.; Blankenberg, S.; Roberts, R.; McPherson, R.; Watkins, H.; Hall, A.S.; Overvad, K.; Rimm, E.; Boerwinkle, E.; Tybjaerg-Hansen, A.; Cupples, L.A.; Reilly, M.P.; Melander, O.; Mannucci, P.M.; Ardissino, D.; Siscovick, D.; Elosua, R.; Stefansson, K.; O'Donnell, C.J.; Salomaa, V.; Rader, D.J.; Peltonen, L.; Schwartz, S.M.; Altshuler, D.; Kathiresan, S. Plasma HDL cholesterol and risk of myocardial infarction: a mendelianrandomisation study. Lancet, 2012, 380(9841), 572-580.
103. Barter, P.J.; Caulfield, M.; Eriksson, M.; Grundy, S.M.; Kastelein, J.J.; Komajda, M.; Lopez-Sendon, J.; Mosca, L.; Tardif, J.C.; Waters, D.D.; Shear, C.L.; Revkin, J.H.; Buhr, K.A.; Fisher, M.R.; Tall, A.R.; Brewer, B. Effects of Torcetrapib in Patients at High Risk for Coronary Events. N. Engl. J. Med., 2007, 357(21), 2109-2122.
104. Schwartz, G.G.; Olsson, A.G.; Abt, M.; Ballantyne, C.M.; Barter, P.J.; Brumm, J.; Chaitman, B.R.; Holme, I.M.; Kallend, D.; Leiter, L.A.; Leitersdorf, E.; McMurray, J.J.; Mundl, H.; Nicholls, S.J.; Shah, P.K.; Tardif, J.C.; Wright, R.S. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med., 2012, 367(22), 2089-2099.
105. Boden, W.E.; Probstfield, J.L.; Anderson, T.; Chaitman, B.R.; svignes-Nickens, P.; Koprowicz, K.; McBride, R.; Teo, K.; Weintraub, W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med., 2011, 365(24), 2255-2267.
106. Sirtori, C.R.; Calabresi, L.; Franceschini, G.; Baldassarre, D.; Amato, M.; Johansson, J.; Salvetti, M.; Monteduro, C.; Zulli, R.; Muiesan, M.L.; Agabiti-Rosei, E. Cardiovascular status of carriers of the apolipoprotein A-IMilanomutant. The Limone sul Garda Study. Circulation, 2001, 103, 1949-1954.
107. Calabresi, L.; Baldassarre, D.; Castelnuovo, S.; Conca, P.; Bocchi, L.; Candini, C.; Frigerio, B.; Amato, M.; Sirtori, C.R.; Alessandrini, P.; Arca, M.; Boscutti, G.; Cattin, L.; Gesualdo, L.; Sampietro, T.; Vaudo, G.; Veglia, F.; Calandra, S.; Franceschini, G. Functionallecithin: cholesterolacyltransferaseisnotrequired for efficientatheroprotection in humans. Circulation, 2009, 120(7), 628-635.
108. Otocka-Kmiecik, A.; Mikhailidis, D.P.; Nicholls, S.J.; Davidson, M.; Rysz, J.; Banach, M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog. Lipid Res., 2012, 51(4), 314-324.
109. Barylski, M.; Toth, P.P.; Nikolic, D.; Banach, M.; Rizzo, M.; Montalto, G. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract. Res. Clin. Endocrinol. Metab., 2014; in press.